CN116917482A - 嵌合蛋白和治疗中枢神经系统疾病的方法 - Google Patents
嵌合蛋白和治疗中枢神经系统疾病的方法 Download PDFInfo
- Publication number
- CN116917482A CN116917482A CN202180067368.8A CN202180067368A CN116917482A CN 116917482 A CN116917482 A CN 116917482A CN 202180067368 A CN202180067368 A CN 202180067368A CN 116917482 A CN116917482 A CN 116917482A
- Authority
- CN
- China
- Prior art keywords
- leu
- ala
- glu
- lys
- ser
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063058888P | 2020-07-30 | 2020-07-30 | |
| US63/058,888 | 2020-07-30 | ||
| PCT/US2021/044019 WO2022026902A2 (en) | 2020-07-30 | 2021-07-30 | Chimeric proteins and methods of use for treatment of central nervous system disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116917482A true CN116917482A (zh) | 2023-10-20 |
Family
ID=80002512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180067368.8A Pending CN116917482A (zh) | 2020-07-30 | 2021-07-30 | 嵌合蛋白和治疗中枢神经系统疾病的方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20220031812A1 (https=) |
| EP (1) | EP4188410B1 (https=) |
| JP (1) | JP2023537318A (https=) |
| CN (1) | CN116917482A (https=) |
| AU (1) | AU2021319203A1 (https=) |
| CA (1) | CA3187734A1 (https=) |
| ES (1) | ES3061325T3 (https=) |
| WO (1) | WO2022026902A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023512423A (ja) | 2019-12-24 | 2023-03-27 | ジュベナ・セラピューティクス・インコーポレイテッド | 再生性ポリペプチドおよびその使用 |
| KR20240029031A (ko) | 2021-06-21 | 2024-03-05 | 쥬베나 테라퓨틱스, 인크. | 재생 폴리펩티드 및 이의 용도 |
| WO2023159067A2 (en) * | 2022-02-15 | 2023-08-24 | Silver Creek Pharmaceuticals, Inc. | Chimeric proteins for treatment of acute radiation syndrome |
| EP4658295A2 (en) * | 2023-02-02 | 2025-12-10 | Silver Creek Pharmaceuticals, Inc. | Methods of treatment using igf-1 chimeric proteins |
| CN116549667B (zh) * | 2023-05-29 | 2024-02-09 | 四川普锐特药业有限公司 | 一种pas修饰的脂质纳米粒、包含其的药物制剂，及其制备方法和用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| JP5577098B2 (ja) * | 2006-12-21 | 2014-08-20 | アムジエン・インコーポレーテツド | ポリペプチドを含有する安定な緩衝化された製剤 |
| ATE502114T1 (de) | 2007-06-21 | 2011-04-15 | Univ Muenchen Tech | Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität |
| CN105524176B (zh) * | 2010-05-21 | 2021-03-19 | 银溪制药股份有限公司 | 双特异性融合蛋白 |
| BR112012029611A2 (pt) | 2010-05-21 | 2017-07-25 | Merrimack Pharmaceuticals Inc | proteína de fusão biespecífica, composição farmacêutica, método de tratamento de dano ao tecido em um indivíduo, método de promoção da regeração ou sobrevivência do tecido em um indivíduo e molécula de ácido nucleico |
| DK2699598T3 (en) * | 2011-04-19 | 2019-04-23 | Pfizer | COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER |
| CN115960249A (zh) | 2015-10-02 | 2023-04-14 | 银溪制药股份有限公司 | 用于组织修复的双特异性治疗性蛋白质 |
-
2021
- 2021-07-30 JP JP2023506330A patent/JP2023537318A/ja active Pending
- 2021-07-30 WO PCT/US2021/044019 patent/WO2022026902A2/en not_active Ceased
- 2021-07-30 ES ES21849618T patent/ES3061325T3/es active Active
- 2021-07-30 US US17/390,206 patent/US20220031812A1/en not_active Abandoned
- 2021-07-30 EP EP21849618.0A patent/EP4188410B1/en active Active
- 2021-07-30 CN CN202180067368.8A patent/CN116917482A/zh active Pending
- 2021-07-30 AU AU2021319203A patent/AU2021319203A1/en active Pending
- 2021-07-30 CA CA3187734A patent/CA3187734A1/en active Pending
-
2025
- 2025-09-08 US US19/321,375 patent/US20260041738A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4188410A2 (en) | 2023-06-07 |
| EP4188410B1 (en) | 2025-11-05 |
| AU2021319203A1 (en) | 2023-03-02 |
| ES3061325T3 (en) | 2026-04-01 |
| JP2023537318A (ja) | 2023-08-31 |
| US20260041738A1 (en) | 2026-02-12 |
| CA3187734A1 (en) | 2022-02-03 |
| WO2022026902A2 (en) | 2022-02-03 |
| US20220031812A1 (en) | 2022-02-03 |
| WO2022026902A3 (en) | 2022-03-10 |
| EP4188410A4 (en) | 2024-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN116917482A (zh) | 嵌合蛋白和治疗中枢神经系统疾病的方法 | |
| JP7143374B2 (ja) | 虚血のための組み合わせ療法 | |
| US8940699B2 (en) | Model systems and treatment regimes for treatment of neurological disease | |
| JP2020045352A (ja) | Ｔａｔ−ＮＲ２Ｂ９ｃの塩化物塩 | |
| US20230055441A1 (en) | Plasmin-resistant peptides for treating stroke and related conditions | |
| US11767344B2 (en) | Pharmaceutically acceptable salts of polypeptides and methods of inhibiting the interaction between psd-95 and n-methyl-d-aspartic acid receptor (nmdar) | |
| US11541098B2 (en) | Peptide composition for treating excitatory neurotoxicity related injuries | |
| US20220211808A1 (en) | Haptoglobin for use in treating an adverse secondary neurological outcome following a haemorrhagic stroke | |
| KR102919967B1 (ko) | 신경 가소성을 유도하기 위한 방법 및 조성물 | |
| CN114555630A (zh) | 用于治疗脊髓损伤和/或髓鞘再生的肽的全身施用 | |
| CN107312071A (zh) | 兴奋性神经毒性相关损伤的治疗方法 | |
| US20240245756A1 (en) | Chimeric proteins and methods of use for treatment of neurodegenerative disorders | |
| CN109072242A (zh) | 用于治疗神经损伤的基于肽的方法 | |
| KR20260006552A (ko) | Igf-1 키메라 단백질을 이용한 치료 방법 | |
| Zheng et al. | The novel PSD-95 inhibitor BXOS110 provides neuroprotection in acute ischemic stroke | |
| WO2026086901A1 (zh) | 用于治疗神经系统疾病的多肽药物组合物及其应用 | |
| WO2017185250A1 (zh) | 兴奋性神经毒性相关损伤的治疗方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |